KR20200069316A - 의료 요법에서의 세마글루타이드 - Google Patents

의료 요법에서의 세마글루타이드 Download PDF

Info

Publication number
KR20200069316A
KR20200069316A KR1020207012311A KR20207012311A KR20200069316A KR 20200069316 A KR20200069316 A KR 20200069316A KR 1020207012311 A KR1020207012311 A KR 1020207012311A KR 20207012311 A KR20207012311 A KR 20207012311A KR 20200069316 A KR20200069316 A KR 20200069316A
Authority
KR
South Korea
Prior art keywords
semaglutide
administered
subject
weight
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020207012311A
Other languages
English (en)
Korean (ko)
Inventor
마리아 카비스취
토마스 한센
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60083831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20200069316(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Publication of KR20200069316A publication Critical patent/KR20200069316A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020207012311A 2017-10-12 2018-10-10 의료 요법에서의 세마글루타이드 Pending KR20200069316A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17196254.1 2017-10-12
EP17196254 2017-10-12
PCT/EP2018/077654 WO2019072941A1 (en) 2017-10-12 2018-10-10 SEMAGLUTIDE IN MEDICAL THERAPY

Publications (1)

Publication Number Publication Date
KR20200069316A true KR20200069316A (ko) 2020-06-16

Family

ID=60083831

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207012311A Pending KR20200069316A (ko) 2017-10-12 2018-10-10 의료 요법에서의 세마글루타이드

Country Status (18)

Country Link
US (5) US12029779B2 (enExample)
EP (1) EP3694538A1 (enExample)
JP (2) JP7148605B2 (enExample)
KR (1) KR20200069316A (enExample)
CN (4) CN120241968A (enExample)
AU (2) AU2018348929B2 (enExample)
BR (1) BR112020006246A2 (enExample)
CA (1) CA3078652A1 (enExample)
CL (1) CL2020000812A1 (enExample)
IL (3) IL322969A (enExample)
MA (1) MA50358A (enExample)
MX (3) MX2020003049A (enExample)
MY (1) MY204827A (enExample)
PH (1) PH12020550185A1 (enExample)
SG (1) SG11202002841PA (enExample)
TW (1) TWI842681B (enExample)
WO (1) WO2019072941A1 (enExample)
ZA (3) ZA202503388B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3078652A1 (en) * 2017-10-12 2019-04-18 Novo Nordisk A/S Semaglutide in medical therapy
US12605426B2 (en) 2020-02-14 2026-04-21 G2Gbio, Inc. Pharmaceutical comprising sustained-release microspheres including GLP-1 analogue or pharmaceutically acceptable salt thereof
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
WO2022212271A1 (en) * 2021-03-29 2022-10-06 Sanford Health Methods and compositions for treating lysosomal storage disorders
AU2023285400A1 (en) * 2022-06-08 2024-12-05 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
WO2024249659A2 (en) * 2023-05-30 2024-12-05 The Medical College Of Wisconsin, Inc. Methods for weight loss and/or reducing weight gain
US12597496B2 (en) * 2023-06-05 2026-04-07 Closed Loop Medicine Ltd. Dosing of incretin pathway drugs
US20260007869A1 (en) 2023-06-23 2026-01-08 Vaxess Technologies, Inc. Microneedle array patches (maps), systems, and methods for manufacturing and using same
US20260199436A1 (en) * 2025-01-16 2026-07-16 Novo Nordisk A/S Semaglutide in medical therapy including weight management

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
ES2298378T3 (es) 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
RU2409349C2 (ru) 2006-04-14 2011-01-20 Маннкайнд Корпорейшн Фармацевтические композиции, содержащие глюкагонподобный пептид(glp-1)
DK2481410T3 (en) 2007-01-31 2016-10-24 Bial - Portela & Ca S A Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen
EP2121897A4 (en) 2007-03-20 2010-03-31 Nippon Kayaku Kk METHOD FOR MONITORING THE DRUG EFFECT ON DIABETES PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
HUE031900T2 (en) 2008-12-10 2017-08-28 Glaxosmithkline Llc Pharmaceutical compositions containing Albiglutide
WO2010092163A2 (en) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Antidiabetic medications
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
MX341025B (es) * 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
CN102203130B (zh) 2010-08-06 2014-06-25 贝达药业股份有限公司 Glp-1衍生物及其应用
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
RU2013133803A (ru) 2010-12-22 2015-01-27 Маркадиа Байотек, Инк. Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
US20140220134A1 (en) 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
SI2753312T1 (sl) 2011-09-08 2017-10-30 Mereo Biopharma 2 Limited Uporaba inhibitorja aromataze za zdravljenje hipogonadizma in sororodnih bolezni
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
HUE049152T2 (hu) * 2012-07-01 2020-09-28 Novo Nordisk As Hosszantartó hatású GLP-1 peptidek alkalmazása
RS58039B1 (sr) * 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
CN117106085A (zh) 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
CA3078652A1 (en) 2017-10-12 2019-04-18 Novo Nordisk A/S Semaglutide in medical therapy

Also Published As

Publication number Publication date
US12295988B2 (en) 2025-05-13
MX2025002188A (es) 2025-04-02
CN111212657A (zh) 2020-05-29
AU2018348929A1 (en) 2020-05-07
US20240316159A1 (en) 2024-09-26
IL273470A (en) 2020-05-31
JP2020536854A (ja) 2020-12-17
JP2022132414A (ja) 2022-09-08
AU2026206205A1 (en) 2026-08-06
MA50358A (fr) 2020-08-19
RU2020114960A (ru) 2021-10-28
SG11202002841PA (en) 2020-04-29
CN119838000A (zh) 2025-04-18
AU2018348929B2 (en) 2025-02-27
US20260232771A1 (en) 2026-08-13
MX2025002189A (es) 2025-04-02
ZA202503388B (en) 2025-09-25
BR112020006246A2 (pt) 2021-03-30
CN119950682A (zh) 2025-05-09
CN120241968A (zh) 2025-07-04
WO2019072941A1 (en) 2019-04-18
EP3694538A1 (en) 2020-08-19
RU2020114960A3 (enExample) 2022-02-11
IL322969A (en) 2025-10-01
TW201914611A (zh) 2019-04-16
ZA202503350B (en) 2025-09-25
US12029779B2 (en) 2024-07-09
US20250235511A1 (en) 2025-07-24
ZA202503387B (en) 2025-09-25
TWI842681B (zh) 2024-05-21
IL322968A (en) 2025-10-01
US20200237876A1 (en) 2020-07-30
PH12020550185A1 (en) 2021-03-01
US12551536B2 (en) 2026-02-17
JP7148605B2 (ja) 2022-10-05
US20240415935A1 (en) 2024-12-19
MY204827A (en) 2024-09-18
CA3078652A1 (en) 2019-04-18
MX2020003049A (es) 2020-07-27
AU2025203535A1 (en) 2025-06-05
CL2020000812A1 (es) 2020-08-14
JP7475398B2 (ja) 2024-04-26

Similar Documents

Publication Publication Date Title
US12551536B2 (en) Semaglutide in medical therapy
EP3541366B1 (en) Buffered formulations of exendin (9-39)
CN103458919A (zh) 在2型糖尿病患者中预防低血糖症
EA034940B1 (ru) Лечение пациентов с сахарным диабетом 2 типа
US20240100127A1 (en) Tirzepatide therapeutic methods
US20240189394A1 (en) Methods of using and compositions containing dulaglutide
KR20230143978A (ko) 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제
EP4090351B1 (en) Dosing regimen of glp-1
RU2800651C2 (ru) Семаглутид в лекарственной терапии
CN115515594A (zh) 高尿酸血症的治疗
US20210220443A1 (en) Method and use of controlling postprandial glucose levels in a subject
BR122025013280A2 (pt) Uso de semaglutida para fabricar uma solução injetável subcutânea para tratar diabetes tipo 2
BR122024015864A2 (pt) Uso de semaglutida para preparação de uma composição farmacêutica para controle de peso
BR122024015868A2 (pt) Uso de semaglutida para preparação de uma composição farmacêutica para tratamento e/ou prevenção de obesidade e/ou de sobrepeso
MX2009012310A (es) Metodo de tratamiento de diabetes tipo 2 que comprende terapia de adicion a metformina.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E14-X000 Pre-grant third party observation filed

St.27 status event code: A-2-3-E10-E14-opp-X000

E14-X000 Pre-grant third party observation filed

St.27 status event code: A-2-3-E10-E14-opp-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E14 Pre-grant third party observation filed

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E14-OPP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E14-X000 Pre-grant third party observation filed

St.27 status event code: A-2-3-E10-E14-opp-X000

E14 Pre-grant third party observation filed

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E14-OPP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E14-X000 Pre-grant third party observation filed

St.27 status event code: A-2-3-E10-E14-opp-X000